Published in:
Open Access
01-08-2016 | Original Article – Cancer Research
Elevated expression of Nodal and YAP1 is associated with poor prognosis of gastric adenocarcinoma
Authors:
Ping Li, Dan Sun, Xiaoting Li, Yingjian He, Wenhui Li, Jing Zhao, Ying Wang, Huan Wang, Yan Xin
Published in:
Journal of Cancer Research and Clinical Oncology
|
Issue 8/2016
Login to get access
Abstract
Purpose
To investigate the correlation between Nodal and YAP1 expression and the clinicopathological characteristics of gastric adenocarcinoma (GAC).
Methods
Quantitative real-time RT-PCR, Western blot, and immunohistochemistry were performed to measure Nodal and YAP1 mRNA and protein in 20 fresh frozen samples and 220 paraffin-embedded GAC tissues with their paired non-tumor mucosa (PNTM). The prognostic values of Nodal and YAP1 were evaluated in 161 GAC patients using univariate and multivariate analyses.
Results
Both mRNA and protein expression of Nodal and YAP1 were significantly increased in GAC compared to PNTM (P < 0.05). Immunohistochemistry showed that Nodal was more highly expressed in 56.4 % GAC samples compared to PNTM; additionally, Nodal expression correlated with depth of tumor invasion, lymph node metastasis, and distant metastasis (all P < 0.05). There was no association between Nodal and YAP1 in GAC (P = 0.171). Kaplan–Meier analysis showed that the outcome of Nodal-high patients was significantly worse than those with low Nodal expression (χ
2 = 30.452, P < 0.001). Cox multivariate regression showed that high Nodal expression was an independent risk factor affecting the prognosis of GAC patients (P = 0.000, RR = 2.976). Furthermore, patients with tumors in which both Nodal and YAP1 were expressed at high levels had the worst prognosis.
Conclusions
Elevated Nodal expression is a marker of poor prognosis in gastric cancer. Patient outcome is further worsened if Nodal and YAP1 are both expressed in the same tumor. The datas we present here suggest that the inhibition of Nodal signaling may represent a new therapeutic strategy for the treatment of gastric adenocarcinoma.